口服Δ9-四氢大麻酚与大麻二酚联用对Δ9-四氢大麻酚药代动力学和药效学的影响:随机临床试验
该随机临床试验在18名健康成人中比较了口服Δ9-THC优势提取物(20 mg Δ9-THC,无CBD)与CBD优势提取物(20 mg Δ9-THC + 640 mg CBD)的药代动力学和药效学。结果显示,与Δ9-THC组相比,Δ9-THC+CBD组Δ9-THC、11-OH-Δ9-THC和Δ9-THC-COOH的Cmax和AUC更高,且自我报告的焦虑、镇静、记忆困难、心率增加以及认知和精神运动功能损害更明显。作者认为CBD抑制Δ9-THC和11-OH-Δ9-THC代谢可能是机制,并指出需要更好理解大麻素-大麻素和大麻素-药物相互作用以指导临床和监管决策。
要点
- 在18名健康成人中,口服20 mg Δ9-THC + 640 mg CBD较20 mg Δ9-THC alone升高Δ9-THC、11-OH-Δ9-THC和Δ9-THC-COOH的Cmax和AUC。
- Δ9-THC+CBD组较Δ9-THC组和安慰剂组增加自我报告的焦虑、镇静、记忆困难,升高心率,并产生更明显的认知和精神运动功能损害。
- CYP混合物+安慰剂布朗尼与CYP混合物未影响任何药效学评估。
- 作者认为CBD抑制Δ9-THC和11-OH-Δ9-THC代谢是观察到的差异的可能机制。
适用人群与场景
- 18名健康成人,平均(SD)年龄30(7)岁,11名男性(61.1%)和7名女性(38.9%),研究开始前至少30天未使用大麻(末次使用大麻平均[SD]天数86[66]天)。
- 在Johns Hopkins University Behavioral Pharmacology Research Unit, Baltimore, MD的门诊实验测试环节中完成。
处置流程与药物剂量
- 参与者随机接受3次门诊实验测试,每次间隔至少1周,干预为布朗尼含:安慰剂(无大麻提取物);Δ9-THC优势提取物(20 mg Δ9-THC,无CBD);CBD优势提取物(20 mg Δ9-THC + 640 mg CBD)。
- 布朗尼在给予细胞色素P450(CYP)探针药物混合物前30分钟给药,混合物含100 mg咖啡因、20 mg奥美拉唑、25 mg氯沙坦、30 mg右美沙芬和2 mg咪达唑仑。
研究设计与关键结果
- 研究类型:随机临床试验,采用参与者内、双盲、交叉设计,于2021年1月至2022年3月进行,18名健康成人完成3次测试。
- 与CYP混合物+Δ9-THC相比,CYP混合物+Δ9-THC+CBD产生更高的Δ9-THC、11-OH-Δ9-THC和Δ9-THC-COOH的Cmax和血浆浓度-时间曲线下面积。
- 与CYP混合物+Δ9-THC和CYP混合物+安慰剂相比,CYP混合物+Δ9-THC+CBD增加自我报告的焦虑、镇静和记忆困难,增加心率,并产生更明显的认知和精神运动功能损害。
- CYP混合物+安慰剂布朗尼与CYP混合物未影响任何药效学评估。
证据类型、等级与局限
- 证据类型:随机临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在相同Δ9-THC剂量下,CBD优势大麻提取物较Δ9-THC优势提取物引起更强的不良反应,这与CBD减轻Δ9-THC不良反应的常见说法矛盾。
- 作者认为,需要更好理解大麻素-大麻素和大麻素-药物相互作用,以指导关于大麻产品治疗性和非治疗性使用的临床和监管决策。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Controlled clinical laboratory studies have shown that cannabidiol (CBD) can sometimes attenuate or exacerbate the effects of Δ9-tetrahydrocannabinol (Δ9-THC). No studies have evaluated differences in pharmacokinetics (PK) of Δ9-THC and pharmacodynamics (PD) between orally administered cannabis extracts that vary with respect to Δ9-THC and CBD concentrations.
OBJECTIVE: To compare the PK and PD of orally administered Δ9-THC-dominant and CBD-dominant cannabis extracts that contained the same Δ9-THC dose (20 mg).
DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial was a within-participant, double-blind, crossover study conducted from January 2021 to March 2022 at the Johns Hopkins University Behavioral Pharmacology Research Unit, Baltimore, MD. Eighteen healthy adults completed 3 randomized outpatient experimental test sessions that were each separated by at least 1 week.
INTERVENTIONS: Brownies containing (1) no cannabis extract (ie, placebo); (2) Δ9-THC-dominant extract (20 mg Δ9-THC with no CBD); and (3) CBD-dominant extract (20 mg Δ9-THC + 640 mg CBD) were administered to participants 30 minutes prior to administering a cytochrome P450 (CYP) probe drug cocktail, which consisted of 100 mg caffeine, 20 mg omeprazole, 25 mg losartan, 30 mg dextromethorphan, and 2 mg midazolam.
MAIN OUTCOMES AND MEASURES: Change-from-baseline plasma concentrations for Δ9-THC or Δ9-THC metabolites and scores for subjective drug effects, cognitive and psychomotor performance, and vital signs. The area under the plasma vs concentration vs time curve (AUC) and maximum plasma concentration (Cmax) were determined.
RESULTS: The participant cohort of 18 adults included 11 males (61.1%) and 7 females (38.9%) with a mean (SD) age of 30 (7) years who had not used cannabis for at least 30 days prior to initiation of the study (mean [SD] day since last cannabis use, 86 [66] days). The CYP cocktail + placebo brownie and the CYP cocktail did not affect any PD assessments. Relative to CYP cocktail + Δ9-THC, CYP cocktail + Δ9-THC + CBD produced a higher Cmax and area under the plasma concentration vs time curve for Δ9-THC, 11-OH-Δ9-THC, and Δ9-THC-COOH. The CYP cocktail + Δ9-THC + CBD increased self-reported anxiety, sedation, and memory difficulty, increased heart rate, and produced a more pronounced impairment of cognitive and psychomotor performance compared with both CYP cocktail + Δ9-THC and CYP cocktail + placebo.
CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of oral Δ9-THC and CBD, stronger adverse effects were elicited from a CBD-dominant cannabis extract compared with a Δ9-THC-dominant cannabis extract at the same Δ9-THC dose, which contradicts common claims that CBD attenuates the adverse effects of Δ9-THC. CBD inhibition of Δ9-THC and 11-OH-Δ9-THC metabolism is the likely mechanism for the differences observed. An improved understanding of cannabinoid-cannabinoid and cannabinoid-drug interactions are needed to inform clinical and regulatory decision-making regarding the therapeutic and nontherapeutic use of cannabis products.
TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT04201197.
参考来源
- Zamarripa CA, Spindle TR, Surujunarain R, et al. Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial. JAMA Netw Open. 2023. PMID: 36780161. doi:10.1001/jamanetworkopen.2022.54752
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。